3.06
-0.11 (-3.47%)
| Previous Close | 3.17 |
| Volume | 425,307 |
| Price / Book | 1.48 |
| 52 Weeks Range |
| Operating Margin (TTM) | -11,193.25% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | -62.40% |
| Total Debt/Equity (MRQ) | 31.69% |
| Current Ratio (MRQ) | 1.69 |
| Operating Cash Flow (TTM) | -31.34 M |
| Levered Free Cash Flow (TTM) | -19.08 M |
| Return on Assets (TTM) | -48.28% |
| Return on Equity (TTM) | -92.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | SAB Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.07 |
|
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.02% |
| % Held by Institutions | 23.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Caligan Partners Lp | 30 Jun 2026 | 7,967,207 |
| Vivo Capital, Llc | 30 Jun 2026 | 7,299,909 |
| Commodore Capital Lp | 30 Jun 2026 | 2,870,000 |
| Spruce Street Capital Lp | 30 Jun 2026 | 2,198,502 |
| Sessa Capital Im, L.P. | 30 Jun 2026 | 2,198,457 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |